Efficacy, Safety, Tolerability And Pharmacokinetics Of Tofacitinib For Treatment Of Systemic Juvenile Idiopathic Arthritis (Sjia) With Active Systemic Features In Children And Adolescent Subjects
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Dec 2017 Planned End Date changed from 1 Apr 2023 to 6 Apr 2023.
- 08 Dec 2017 Planned primary completion date changed from 1 Apr 2023 to 6 Apr 2023.
- 08 Dec 2017 Planned initiation date changed from 1 Jan 2018 to 19 Jan 2018.